“With the scramble for viral and antibody testing kits, and the ultimate goal of finding a vaccine for Covid-19, many biotech companies are suddenly in the spotlight. Even those that aren’t directly working on a Covid-related solution look more attractive,” observes the author of today’s article, who also singles out biotech stocks as being the one possible bright spot in the current, challenging market environment. For seven biotech stocks he highlights as particularly well positioned for a nice payoff, CLICK HERE.
In a bullish take on current circumstances, Morgan Stanley’s head of U.S. equity strategy argued in a recent note to clients that the current state of the market appears remarkably similar to that of March 2009, when the S&P 500 began the longest-running bull market in history. With this view in mind, risk-tolerant investors may want to identify compelling yet affordable names, especially in the biotech space. Today’s article highlights three such biotech stocks, all of which have earned “Strong Buy” consensus ratings, are trading for under $5, and sport “colossal upside potential.” For more, CLICK HERE.
It should come as no surprise that one of the top biotech stocks to consider right now, as identified by the author of today’s article, is a coronavirus play whose COVID-19 vaccine candidate has just been approved by the FDA for Phase II clinical trials: Moderna. For the author’s other two top picks from the “recession-proof” biotech sector – which he notes could grow to $775 billion by 2024 – CLICK HERE.
With a massive cash balance (and no debt), rapidly growing revenue and earnings, and a well-stocked pipeline, the pharma stock that’s the focus of today’s article, trading at just six times earnings, would appear on the surface to be a great pick for value investors. The author cautions, however, that “there’s a solid bearish argument that is scaring investors away from the stock” – and he examines the validity of the various claims underlying this argument. For more, CLICK HERE.
While the broader market has been all over the place over the past few months, one area that has performed significantly better than the S&P 500 is the biotech sector. Of course, while promising clinical trial results or regulatory approval of a treatment can serve as the catalyst that sends shares of biotech companies soaring, it’s critical to separate the biotechs poised for massive growth from those destined for failure. Today’s article highlights three biotech stocks that are all Buy-rated, trading under $4 a share, and have at least 50% upside potential. For more, CLICK HERE.
Looking for “exciting biotech plays that won’t break the bank”? Today’s article highlights three such plays, all of which are trading under $3 per share, are Buy-rated, and “boast colossal long-term growth prospects, with upside potential of at least 200%.” For the names and details of these three biotech stocks, CLICK HERE.
The small-cap biotech highlighted in today’s article has had mixed clinical results when it comes to one of its novel cancer immunotherapy candidates. The author, however, advises that “Despite the uncertainty surrounding [the candidate], investors shouldn’t be dismayed. Usually, when investing in small-cap biotech stocks, what’s far more important in the decision-making process is to see whether the company is backed by institutional investors” – and not only does this firm have institutional backing, but it also has a number of research and development partnerships with big pharma players. For more on this stock that may appeal to biotech investors with a high risk tolerance – CLICK HERE.
Heightened volatility across most asset classes over the last two months has led to a surge in trading volumes – and to exchange stocks (the companies that facilitate the trading of equities, derivatives and commodities) moving higher. Today’s article examines the recent trading activity of three leading exchanges – and identifies possible swing trading opportunities for each. For more, CLICK HERE.
Some sectors are holding up much better than others in the current market environment – and offering compelling plays in the process. One of those sectors is biotech where, today’s article notes, “the pros say there are names that have not only received a lot of love from the analyst community, but also stand to deliver hefty returns through 2020 and beyond.” For three biotech stocks that have garnered “Strong Buy” analyst ratings and that have plenty of upside potential based on analyst price targets, CLICK HERE.
After three straight months of losses, April brought the S&P 500 health care sector its best one-month gain in twenty years, and today’s article notes that “The sector’s top performing stocks were diagnostic firms at the heart of the Covid-19 testing expansion.” Moreover, the biotech sector outpaced both the health care sector and the overall market, again with Covid-related biotech stocks being among the best performers. For more on biotech’s recent performance – and whether it can last – CLICK HERE.